Carmen J Allegra,
Professor Emeritus/Courtesy Faculty
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7766
Business Email:
carmen.allegra@medicine.ufl.edu
Publications
2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[DOI] 10.1200/JCO.23.01080.
[PMID] 38315963.
2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Future oncology (London, England).
[DOI] 10.2217/fon-2022-0392.
[PMID] 36399037.
2022
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Journal of hematology & oncology.
15(1)
[DOI] 10.1186/s13045-022-01241-3.
[PMID] 35260176.
2022
Clinical Benefit Scales and Trial Design: Some Statistical Issues.
Journal of the National Cancer Institute.
114(9):1222-1227
[DOI] 10.1093/jnci/djac099.
[PMID] 35583264.
2022
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Journal of surgical oncology.
126(8):1494-1503
[DOI] 10.1002/jso.27078.
[PMID] 36111443.
2021
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
Journal of the National Cancer Institute.
113(12):1693-1704
[DOI] 10.1093/jnci/djab123.
[PMID] 34405233.
2021
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
39(6):642-651
[DOI] 10.1200/JCO.20.01600.
[PMID] 33356421.
2021
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
27(6):1612-1622
[DOI] 10.1158/1078-0432.CCR-20-1831.
[PMID] 33203645.
2021
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
The oncologist.
26(10):825-e1674
[DOI] 10.1002/onco.13853.
[PMID] 34101295.
2021
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
39(4):285-294
[DOI] 10.1200/JCO.20.01994.
[PMID] 33356422.
2021
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Journal of the National Cancer Institute.
113(4):400-407
[DOI] 10.1093/jnci/djaa124.
[PMID] 32835356.
2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast cancer research : BCR.
22(1)
[DOI] 10.1186/s13058-019-1240-y.
[PMID] 31969184.
2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Nature reviews. Clinical oncology.
17(12):757-770
[DOI] 10.1038/s41571-020-0392-0.
[PMID] 32632268.
2020
Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
18(12):2717-2723.e3
[DOI] 10.1016/j.cgh.2019.11.046.
[PMID] 31811950.
2020
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?
Journal of the National Cancer Institute.
112(8):773-778
[DOI] 10.1093/jnci/djz240.
[PMID] 31868907.
2019
5-FU induced cardiotoxicity: case series and review of the literature.
Cardio-oncology (London, England).
5
[DOI] 10.1186/s40959-019-0048-3.
[PMID] 32154019.
2019
Can We Find the Positive in Negative Clinical Trials?
Journal of the National Cancer Institute.
111(7):637-638
[DOI] 10.1093/jnci/djz082.
[PMID] 31077298.
2019
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
Journal of the National Cancer Institute.
111(11):1131-1141
[DOI] 10.1093/jnci/djz093.
[PMID] 31322663.
2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast cancer research : BCR.
21(1)
[DOI] 10.1186/s13058-019-1196-y.
[PMID] 31796073.
2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
37(29):2601-2609
[DOI] 10.1200/JCO.19.00858.
[PMID] 31442103.
2019
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.
Clinical pharmacology and therapeutics.
105(3):598-613
[DOI] 10.1002/cpt.1124.
[PMID] 29923599.
2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
PloS one.
13(8)
[DOI] 10.1371/journal.pone.0200836.
[PMID] 30118499.
2018
Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
Journal of the National Cancer Institute.
110(5):460-466
[DOI] 10.1093/jnci/djx228.
[PMID] 29165692.
2018
Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
Cancer.
124(17):3510-3519
[DOI] 10.1002/cncr.31527.
[PMID] 29984547.
2018
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
British journal of cancer.
118(5):629-633
[DOI] 10.1038/bjc.2017.448.
[PMID] 29241223.
2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
JAMA oncology.
3(4):472-480
[DOI] 10.1001/jamaoncol.2016.5469.
[PMID] 28006055.
2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer.
American journal of clinical pathology.
147(3):221-260
[DOI] 10.1093/ajcp/aqw209.
[PMID] 28165529.
2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
The Journal of molecular diagnostics : JMD.
19(2):187-225
[DOI] 10.1016/j.jmoldx.2016.11.001.
[PMID] 28185757.
2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
Archives of pathology & laboratory medicine.
141(5):625-657
[DOI] 10.5858/arpa.2016-0554-CP.
[PMID] 28165284.
2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
35(13):1453-1486
[DOI] 10.1200/JCO.2016.71.9807.
[PMID] 28165299.
2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
Journal of oncology practice.
13(5):333-337
[DOI] 10.1200/JOP.2017.022152.
[PMID] 28350513.
2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
JAMA oncology.
2(9):1162-9
[DOI] 10.1001/jamaoncol.2016.2314.
[PMID] 27270348.
2016
Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.
Journal of gastrointestinal oncology.
7(2):173-80
[DOI] 10.3978/j.issn.2078-6891.2015.071.
[PMID] 27034783.
2016
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.
Journal of oncology practice.
12(2):180-1
[DOI] 10.1200/JOP.2015.007898.
[PMID] 26443838.
2016
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
34(2):179-85
[DOI] 10.1200/JCO.2015.63.9674.
[PMID] 26438111.
2016
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
34(8):843-53
[DOI] 10.1200/JCO.2015.63.0558.
[PMID] 26811529.
2015
JNCI is 75 years old!
Journal of the National Cancer Institute.
107(1)
[DOI] 10.1093/jnci/dju406.
[PMID] 25564599.
2015
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Journal of the National Cancer Institute.
107(11)
[DOI] 10.1093/jnci/djv248.
[PMID] 26374429.
2015
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.
Current colorectal cancer reports.
11(5):275-280
[PMID] 26321890.
2015
Selective high ligation of the sapheno-femoral junction decreases the neovascularization and the recurrent varicose veins in the operated groin.
International angiology : a journal of the International Union of Angiology.
34(3):250-6
[PMID] 25027600.
2015
The Master Protocol Concept.
Seminars in oncology.
42(5):724-30
[DOI] 10.1053/j.seminoncol.2015.07.009.
[PMID] 26433553.
2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.
Journal of the National Cancer Institute.
106(12)
[DOI] 10.1093/jnci/dju333.
[PMID] 25359867.
2014
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
European journal of cancer (Oxford, England : 1990).
50(2):320-31
[DOI] 10.1016/j.ejca.2013.09.013.
[PMID] 24140268.
2014
Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
International journal of cancer.
135(1):128-37
[DOI] 10.1002/ijc.28675.
[PMID] 24347111.
2014
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
32(18):1927-34
[DOI] 10.1200/JCO.2013.53.7753.
[PMID] 24799484.
2014
Nsabp Fc-6: Phase II Study To Determine Surgical Conversion Rate in Patients (Pts) Receiving Neoadjuvant (Na) Mfolfox7 Plus Dose-Escalating Cetuximab (C) for Unresectable K-Ras Wild-Type (Wt) Colorectal Cancer With Metastases (Mcrc) Confined To the Liver
.
21(1)
2014
Quality of live as measured by the CIVQ 20. Questionnaire following oral mesoglycan treatment of patients with chronic venous disease.
International angiology : a journal of the International Union of Angiology.
33(5):407-18
[PMID] 24566500.
2014
Response.
Journal of the National Cancer Institute.
106(4)
[DOI] 10.1093/jnci/dju059.
[PMID] 24659792.
2013
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
31(3):359-64
[DOI] 10.1200/JCO.2012.44.4711.
[PMID] 23233715.
2013
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Journal of the National Cancer Institute.
105(13):989-92
[DOI] 10.1093/jnci/djt140.
[PMID] 23821759.
2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
British journal of cancer.
109(7):1735-43
[DOI] 10.1038/bjc.2013.523.
[PMID] 24045663.
2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
30(28):3499-506
[PMID] 22949147.
2012
Aflibercept Versus Placebo in Combination With Folfiri in Previously Treated Metastatic Colorectal Cancer: Mean Overall Survival for Subgroups From Velour
Annals of Oncology.
23
2012
Aflibercept/Folfiri (Af) Vs Placebo/Folfiri (Pf) in Metastatic Colorectal Cancer (Mcrc): Post-Hoc Analysis of Survival Excluding Adjuvant (Adj)-Only Patients in the Velour Trial
Annals of Oncology.
23
2012
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.
Therapeutic advances in medical oncology.
4(6):301-19
[DOI] 10.1177/1758834012454464.
[PMID] 23118806.
2012
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
30(4):406-12
[DOI] 10.1200/JCO.2011.39.2563.
[PMID] 22203756.
2012
Sensitivity Analyses of Progression-Free Survival (Pfs) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (Mcrc): Results From the Velour Study
Annals of Oncology.
23:198-199
2012
The Journal of the National Cancer Institute: the next generation.
Journal of the National Cancer Institute.
104(13):961-2
[DOI] 10.1093/jnci/djs276.
[PMID] 22751900.
2012
The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report.
Case reports in pathology.
2012
[DOI] 10.1155/2012/425967.
[PMID] 23119210.
2011
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy–an Aide et Recherche en Cancerologie Digestive Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
29(31):4199-204
[DOI] 10.1200/JCO.2011.35.5867.
[PMID] 21969501.
2011
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
Oncology reviews.
5(3):177-184
[PMID] 21949574.
2011
Combination therapy for renal cell cancer: what are possible options?
Oncology.
81(3-4):220-9
[DOI] 10.1159/000333470.
[PMID] 22085914.
2011
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Journal of the National Cancer Institute.
103(11):863-75
[DOI] 10.1093/jnci/djr153.
[PMID] 21597022.
2011
Intravenous (Iv) Aflibercept Versus Placebo in Combination With Irinotecan/5-Fu (Folfiri) for Second-Line Treatment of Metastatic Colorectal Cancer (Mcrc): Results of a Multinational Phase III Trial (Efc10262-Velour).
Annals of Oncology.
22
2011
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Journal of the National Cancer Institute.
103(1):4-5
[DOI] 10.1093/jnci/djq483.
[PMID] 21123834.
2011
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
29(28):3768-74
[DOI] 10.1200/JCO.2011.36.4539.
[PMID] 21859995.
2011
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
29(1):11-6
[DOI] 10.1200/JCO.2010.30.0855.
[PMID] 20940184.
2010
Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
Clinical advances in hematology & oncology : H&O.
8(7):499-504
[PMID] 20864918.
2010
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
Journal of the National Cancer Institute.
102(3):161-9
[DOI] 10.1093/jnci/djp485.
[PMID] 20071686.
2009
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
27(12):2091-6
[DOI] 10.1200/JCO.2009.21.9170.
[PMID] 19188670.
2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
27(20):3385-90
[DOI] 10.1200/JCO.2009.21.9220.
[PMID] 19414665.
2009
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).
NIH consensus and state-of-the-science statements.
26(2):1-27
[PMID] 19784089.
2009
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
27(31):5124-30
[DOI] 10.1200/JCO.2009.22.0467.
[PMID] 19770376.
2009
The CEAP-L classification for lymphedemas of the limbs: the Italian experience.
International angiology : a journal of the International Union of Angiology.
28(4):315-24
[PMID] 19648876.
2009
The marriage of growth factor inhibitors and chemotherapy: bliss or bust?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
27(10):1545-8
[DOI] 10.1200/JCO.2008.20.3224.
[PMID] 19224842.
2008
Don Quixote and the quest for personalized medicine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
26(16):2619-20
[DOI] 10.1200/JCO.2008.16.8922.
[PMID] 18509173.
2008
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
26(13):2118-23
[DOI] 10.1200/JCO.2007.15.2090.
[PMID] 18445840.
2007
End points in advanced colon cancer clinical trials: a review and proposal.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
25(24):3572-5
[PMID] 17704403.
2007
Predictive value of microsatellite instability-high remains controversial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
25(30):4857; author reply 4857-8
[PMID] 17947740.
2007
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
25(7):767-72
[PMID] 17228023.
2007
Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.
Oncogene.
26(33):4817-24
[PMID] 17297449.
2006
How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599.
The oncologist.
11(1):31-8
[PMID] 16401711.
2006
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Clinical cancer research : an official journal of the American Association for Cancer Research.
12(9):2738-44
[PMID] 16675565.
2005
Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors’ Treatment Plans and Relevant Phase III Trial Data.
Journal of oncology practice.
1(2):37-42
[PMID] 20871677.
2005
Adjuvant therapy for colon cancer–the pace quickens.
The New England journal of medicine.
352(26):2746-8
[PMID] 15987925.
2005
Clinical trial designs for predictive marker validation in cancer treatment trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
23(9):2020-7
[PMID] 15774793.
2005
Cytotoxins and cancer immunotherapy: the dance of the macabre?
Journal of the National Cancer Institute.
97(19):1396-7
[PMID] 16204684.
2005
Prevalence of burnout in the u.s. Oncology community: results of a 2003 survey.
Journal of oncology practice.
1(4):140-7
[PMID] 20871697.
2004
A randomised controlled study of four-layer compression versus Unna’s Boot for venous ulcers.
Journal of wound care.
13(1):21-4
[PMID] 14969023.
2004
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.
Cancer cell.
5(4):341-51
[PMID] 15093541.
2003
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Cancer research.
63(15):4602-6
[PMID] 12907638.
2003
Microsatellite instability in colon cancer.
The New England journal of medicine.
349(18):1774-6; author reply 1774
[PMID] 14585950.
2003
Molecular diagnostics: assays, tissues, progress, and pitfalls.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
21(3):395-6
[PMID] 12560423.
2003
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
21(2):241-50
[PMID] 12525515.
2003
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
21(5):815-9
[PMID] 12610179.
2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
20(7):1735-43
[PMID] 11919229.
2002
The identification of thymidylate synthase peptide domains located in the interface region that bind thymidylate synthase mRNA.
Biochemical and biophysical research communications.
297(1):24-31
[PMID] 12220503.
2002
Thymidylate synthase levels: prognostic, predictive, or both?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
20(7):1711-3
[PMID] 11919223.
2001
Development of human anti-thymidine kinase antibodies.
Anti-cancer drugs.
12(6):555-9
[PMID] 11460003.
2001
Downregulation of p21/WAF1 expression by thymidylate synthase.
Biochemical and biophysical research communications.
285(2):195-200
[PMID] 11444825.
2001
Hematological Complications of Acute Pancreatitis: A Review.
Resident and staff physician.
47(10):29-35
[PMID] 34764519.
2001
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Cancer chemotherapy and pharmacology.
47(2):117-25
[PMID] 11269737.
2001
Physical interaction between p53 and primary response gene Egr-1.
International journal of oncology.
18(4):863-70
[PMID] 11251186.
2001
Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology.
12(1):123-9
[PMID] 11249039.
2001
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
7(3):562-9
[PMID] 11297249.
2001
Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute’s Anticancer Drug Screen.
Clinical cancer research : an official journal of the American Association for Cancer Research.
7(4):999-1009
[PMID] 11309351.
2001
Tumor marker expression is predictive of survival in patients with esophageal cancer.
The Annals of thoracic surgery.
72(3):859-66
[PMID] 11565671.
2001
Von Willebrand Disease and Pregnancy.
Consultant.
41(3):445-451
[PMID] 35450029.
2000
Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
Cancer journal (Sudbury, Mass.).
6(4):234-42
[PMID] 11038143.
2000
Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA.
Nucleic acids research.
28(6):1381-9
[PMID] 10684933.
2000
Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt’s lymphoma.
Molecular and cellular biology.
20(14):5276-84
[PMID] 10866684.
2000
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochemical and biophysical research communications.
268(1):183-91
[PMID] 10652234.
2000
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Cancer chemotherapy and pharmacology.
45(5):409-16
[PMID] 10803925.
2000
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
Clinical cancer research : an official journal of the American Association for Cancer Research.
6(5):1720-30
[PMID] 10815890.
2000
Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells.
The Biochemical journal.
345 Pt 3(Pt 3):535-41
[PMID] 10642512.
2000
Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
6(9):3522-9
[PMID] 10999739.
2000
Multiprotein complexes present at the MIF motifs flanking the promoter of the human c-myc gene.
FEBS letters.
474(1):23-8
[PMID] 10828444.
2000
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
18(3):659-67
[PMID] 10653882.
2000
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
British journal of cancer.
82(3):560-7
[PMID] 10682666.
2000
Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin’s disease.
Leukemia & lymphoma.
39(3-4):421-6
[PMID] 11342324.
1999
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(9):2381-91
[PMID] 10499608.
1999
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.
Journal of immunotherapy (Hagerstown, Md. : 1997).
22(2):155-65
[PMID] 10093040.
1999
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(9):2399-408
[PMID] 10499610.
1999
Antifolates: the next millennium.
Seminars in oncology.
26(2 Suppl 6):1-2
[PMID] 10598548.
1999
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
18:1-38
[PMID] 10800475.
1999
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(8):1947-9
[PMID] 10473070.
1999
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(6):1347-52
[PMID] 10389918.
1999
Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.
Molecular and cellular biology.
19(2):1582-94
[PMID] 9891091.
1998
5-fluorouracil-mediated thymidylate synthase induction in malignant and nonmalignant human cells.
Biochemical pharmacology.
56(2):231-5
[PMID] 9698077.
1998
Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.
Journal of the National Cancer Institute.
90(23):1810-6
[PMID] 9839521.
1998
Epitope mapping of a series of human thymidylate synthase monoclonal antibodies.
Cancer research.
58(12):2606-11
[PMID] 9635586.
1998
Functional transplantation of the rat pituitary gland.
Neurosurgery.
43(5):1157-63
[PMID] 9802859.
1998
Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma.
Molecular pharmacology.
53(2):252-61
[PMID] 9463483.
1998
The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.
Oncology reports.
5(3):559-67
[PMID] 9538153.
1997
A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Clinical cancer research : an official journal of the American Association for Cancer Research.
3(7):1125-34
[PMID] 9815792.
1997
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
17:1-39
[PMID] 9551206.
1997
Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Oncology research.
9(2):77-88
[PMID] 9167189.
1997
Immunohistochemical determination of thymidylate synthase in colorectal cancer–methodological studies.
European journal of cancer (Oxford, England : 1990).
33(13):2278-81
[PMID] 9470819.
1997
Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
Cancer chemotherapy and pharmacology.
40(2):117-25
[PMID] 9182832.
1997
LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor.
Genes, chromosomes & cancer.
18(3):232-9
[PMID] 9071577.
1997
Neutrophilia and organomegaly in two patients with cancer.
Hospital practice (1995).
32(1):135-6, 139
[PMID] 9064302.
1997
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
15(4):1492-501
[PMID] 9193345.
1997
Prognostic importance of thymidylate synthase expression in early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
15(5):1923-31
[PMID] 9164203.
1997
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Journal of the National Cancer Institute.
89(4):308-13
[PMID] 9048835.
1996
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
16:1-27
[PMID] 8639379.
1996
Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells.
Biochemical pharmacology.
51(12):1649-59
[PMID] 8687480.
1996
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
The American journal of tropical medicine and hygiene.
54(3):249-52
[PMID] 8600759.
1996
Identification of in vivo target RNA sequences bound by thymidylate synthase.
Nucleic acids research.
24(16):3222-8
[PMID] 8774904.
1996
Mechanisms of clinical resistance to 5-fluorouracil chemotherapy.
Cancer treatment and research.
87:175-95
[PMID] 8886453.
1996
New concepts for the development and use of antifolates.
Stem cells (Dayton, Ohio).
14(1):41-6
[PMID] 8820950.
1996
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
14(4):1236-44
[PMID] 8648379.
1996
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
14(6):1798-809
[PMID] 8656248.
1996
Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma.
Cancer.
77(12):2432-9
[PMID] 8640689.
1996
Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease.
Seminars in thrombosis and hemostasis.
22 Suppl 1:35-40
[PMID] 8807727.
1996
Postphlebitic syndrome: clinical activity and tolerability of desmin, new LMW dermatan sulfate.
Angiology.
47(10):1001-10
[PMID] 8873586.
1996
Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
Biochemical pharmacology.
51(10):1349-55
[PMID] 8787551.
1996
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2(3):477-81
[PMID] 9816193.
1996
The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.
European journal of cancer (Oxford, England : 1990).
32A(12):2148-54
[PMID] 9014759.
1996
The role of thymidylate synthase as an RNA binding protein.
BioEssays : news and reviews in molecular, cellular and developmental biology.
18(3):191-8
[PMID] 8867733.
1996
The role of thymidylate synthase in cellular regulation.
Advances in enzyme regulation.
36:143-63
[PMID] 8869745.
1995
Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.
Anti-cancer drugs.
6(1):154-7
[PMID] 7538828.
1995
Characterization of a specific interaction between Escherichia coli thymidylate synthase and Escherichia coli thymidylate synthase mRNA.
Nucleic acids research.
23(5):869-75
[PMID] 7708505.
1995
Colorectal cancer biology: clinical implications.
Seminars in oncology.
22(5):418-32
[PMID] 7570055.
1995
Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
Molecular pharmacology.
48(2):305-15
[PMID] 7651364.
1995
Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus.
Cancer.
75(2):423-9
[PMID] 7812911.
1995
Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels.
Journal of the National Cancer Institute.
87(20):1558-9
[PMID] 7563193.
1995
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.
British journal of cancer.
71(6):1151-7
[PMID] 7779704.
1995
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
JAMA.
273(3):236-9
[PMID] 7807664.
1995
Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Cancer chemotherapy and pharmacology.
36(6):513-23
[PMID] 7554044.
1995
Tamoxifen, uridine transport, and dome formation in human breast cancer cells.
The cancer journal from Scientific American.
1(3):182-3
[PMID] 9166472.
1995
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.
British journal of cancer.
71(6):1145-50
[PMID] 7779703.
1995
The role of interferon-alpha as a modulator of fluorouracil and leucovorin.
European journal of cancer (Oxford, England : 1990).
31A(7-8):1316-20
[PMID] 7577043.
1995
Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro.
Molecular and cellular biology.
15(1):179-85
[PMID] 7799924.
1995
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
Biochemical pharmacology.
49(10):1419-26
[PMID] 7763285.
1995
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Cancer research.
55(7):1407-12
[PMID] 7882343.
1994
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications.
655(1):97-104
[PMID] 8061838.
1994
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
15:1-31
[PMID] 7779582.
1994
Determinants of trimetrexate lethality in human colon cancer cells.
British journal of cancer.
70(6):1075-84
[PMID] 7981057.
1994
Dihydropteroate synthetase antibodies.
The Journal of infectious diseases.
169(6):1414-5
[PMID] 8195633.
1994
Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Oncology research.
6(12):581-91
[PMID] 7787251.
1994
Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells.
Molecular and cellular biology.
14(1):207-13
[PMID] 8264588.
1994
Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone).
The Journal of infectious diseases.
169(2):456-9
[PMID] 8106784.
1994
Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.
Cancer chemotherapy and pharmacology.
34(6):491-6
[PMID] 7522978.
1994
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Cancer treatment reviews.
20(1):11-49
[PMID] 7507404.
1994
The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA.
The Journal of biological chemistry.
269(32):20289-93
[PMID] 8051122.
1994
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
12(12):2640-7
[PMID] 7989939.
1993
A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma.
Cancer.
72(3):663-8
[PMID] 8334622.
1993
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
14:1-25
[PMID] 8312100.
1993
Clinical use of leucovorin: intracellular metabolism.
Advances in experimental medicine and biology.
339:43-9; discussion 55
[PMID] 8178727.
1993
Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Advances in experimental medicine and biology.
339:119-23
[PMID] 8178710.
1993
Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA.
The Journal of biological chemistry.
268(28):21438-42
[PMID] 8407987.
1993
Identification of an RNA binding site for human thymidylate synthase.
Proceedings of the National Academy of Sciences of the United States of America.
90(2):517-21
[PMID] 8421684.
1993
Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.
Anti-cancer drugs.
4(4):431-5
[PMID] 8400344.
1993
Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.
Antimicrobial agents and chemotherapy.
37(6):1227-31
[PMID] 7687120.
1993
Leucovorin modulation of fluorouracil.
Oncology (Williston Park, N.Y.).
7(8):63-72; discussion 75
[PMID] 8398636.
1993
Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Anti-cancer drugs.
4(5):545-54
[PMID] 8292811.
1993
Measurement of cyclopentenyl cytosine 5′-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.
Analytical biochemistry.
213(1):90-6
[PMID] 8238887.
1993
Neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma.
Oncology (Williston Park, N.Y.).
7(5):37-42; discussion 42
[PMID] 8512781.
1993
Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay.
Biochemical pharmacology.
45(12):2483-6
[PMID] 8328986.
1993
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Molecular pharmacology.
43(4):527-33
[PMID] 8474431.
1993
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Advances in experimental medicine and biology.
339:143-51; discussion 165
[PMID] 8178713.
1993
Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
2(3):229-34
[PMID] 8318875.
1993
Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro.
Biochemistry.
32(18):4756-60
[PMID] 8490020.
1992
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
Gynecologic oncology.
46(3):326-9
[PMID] 1526510.
1992
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
13:1-30
[PMID] 1389906.
1992
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Seminars in oncology.
19(2 Suppl 3):36-44
[PMID] 1557656.
1992
Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Journal of the National Cancer Institute.
84(23):1820-5
[PMID] 1433371.
1992
Enzyme studies of methotrexate-resistant human leukemic cell (K562) subclones.
Leukemia research.
16(6-7):565-9
[PMID] 1378915.
1992
Identification of a protein factor secreted by 3T3-L1 preadipocytes inhibitory for the human MCF-7 breast cancer cell line.
Cancer research.
52(24):6860-5
[PMID] 1458474.
1992
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Cancer research.
52(16):4306-12
[PMID] 1643628.
1992
Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines.
Cancer research.
52(1):36-44
[PMID] 1370075.
1992
Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells.
Biochemical pharmacology.
43(7):1587-99
[PMID] 1567480.
1992
Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin.
Anti-cancer drugs.
3(5):463-9
[PMID] 1450439.
1991
5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study.
American journal of clinical oncology.
14(1):30-2
[PMID] 1987734.
1991
A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
Seminars in thrombosis and hemostasis.
17 Suppl 2:228-34
[PMID] 1948094.
1991
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
12:1-25
[PMID] 1834143.
1991
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.
Proceedings of the National Academy of Sciences of the United States of America.
88(20):8977-81
[PMID] 1924359.
1991
Biochemical modulation: a modality that has come of therapeutic age.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
9(10):1723-6
[PMID] 1919622.
1991
Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Molecular pharmacology.
39(2):136-43
[PMID] 1704999.
1991
Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue.
Cancer research.
51(24):6668-76
[PMID] 1720706.
1991
Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Biochemical pharmacology.
42(2):409-18
[PMID] 1713459.
1990
A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Investigational new drugs.
8(2):159-66
[PMID] 2143500.
1990
Antimetabolites.
Cancer chemotherapy and biological response modifiers.
11:1-28
[PMID] 2223392.
1990
Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii.
Experimental parasitology.
71(1):60-8
[PMID] 2354716.
1990
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
International journal of cancer.
46(1):101-5
[PMID] 2163987.
1990
Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
Cancer research.
50(22):7279-84
[PMID] 1699659.
1990
Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
Cancer research.
50(18):5834-40
[PMID] 1697502.
1990
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).
Cancer research.
50(12):3574-8
[PMID] 1692762.
1990
Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.
The Journal of clinical investigation.
85(2):371-9
[PMID] 2298911.
1990
Isolation and characterization of a novel dihydrofolate formylating enzyme from human MCF-7 breast cancer cells.
Biochemical pharmacology.
39(3):615-8
[PMID] 2306274.
1990
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.
Biochemical pharmacology.
40(12):2651-60
[PMID] 2260989.
1990
Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells.
The Journal of biological chemistry.
265(15):8470-8
[PMID] 2341391.
1990
Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Molecular pharmacology.
38(3):410-7
[PMID] 2402230.
1990
Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia.
The Journal of infectious diseases.
161(1):91-6
[PMID] 2136905.
1989
Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
The Journal of infectious diseases.
160(2):312-20
[PMID] 2527275.
1989
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
7(7):890-9
[PMID] 2661735.
1989
Folate cycle kinetics in human breast cancer cells.
The Journal of biological chemistry.
264(18):10552-66
[PMID] 2732237.
1989
Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line.
Biochemical pharmacology.
38(1):51-9
[PMID] 2462882.
1989
NIH conference. Pneumocystis pneumonia: from bench to clinic.
Annals of internal medicine.
111(10):813-26
[PMID] 2683916.
1989
Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells.
Journal of the National Cancer Institute.
81(18):1413-7
[PMID] 2778828.
1988
Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.
Antimicrobial agents and chemotherapy.
32(3):324-6
[PMID] 2966610.
1988
Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
The American journal of tropical medicine and hygiene.
39(5):491-6
[PMID] 2973755.
1988
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.
Journal of the National Cancer Institute.
80(19):1560-4
[PMID] 2973527.
1988
High dose intravenous methotrexate with leucovorin rescue in rheumatoid arthritis.
The Journal of rheumatology.
15(2):251-5
[PMID] 3258915.
1988
Identification and biochemical properties of 10-formyldihydrofolate, a novel folate found in methotrexate-treated cells.
The Journal of biological chemistry.
263(15):7105-11
[PMID] 3366769.
1988
Inhibition of folate-dependent enzymes by 7-OH-methotrexate.
Biochemical pharmacology.
37(18):3531-4
[PMID] 2458733.
1988
Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Antimicrobial agents and chemotherapy.
32(4):430-3
[PMID] 2967669.
1988
The treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.
Advances in experimental medicine and biology.
244:107-12
[PMID] 3266821.
1988
Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS).
Seminars in oncology.
15(2 Suppl 2):46-9
[PMID] 2966985.
1987
Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
The Journal of biological chemistry.
262(28):13520-6
[PMID] 2443493.
1987
Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.
NCI monographs : a publication of the National Cancer Institute.
(5):199-202
[PMID] 3501543.
1987
Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
The New England journal of medicine.
317(16):978-85
[PMID] 2958710.
1985
Measuring levels of methotrexate.
The New England journal of medicine.
313(3)
[PMID] 3892295.
1985
Polyglutamation of methotrexate. Is methotrexate a prodrug?
The Journal of clinical investigation.
76(3):907-12
[PMID] 2413074.
1985
Raynaud’s disease: a new therapeutic approach with a 5-HT2 receptors blocker.
Bollettino chimico farmaceutico.
124(10):121S-124S
[PMID] 2935173.
1984
Cancer chemotherapy. Progress and expectations, 1984.
Cancer.
54(11 Suppl):2599-608
[PMID] 6388809.
Grants
Mar 2016
– Feb 2020
Allegra IPA
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Mar 2015
– Feb 2016
Integrated Translational Genoproteomics Center
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS
via NATL INST OF HLTH NCI
Mar 2014
– Feb 2016
NRG Oncology Network Group Operations Center
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Dec 2013
– Dec 2017
A PHASE I/II DOSE-ESCALATION STUDY EVALUATING THE COMBINATION OF NERATINIB AND CETUXIMAB IN PATIENTS . . .
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Dec 2013
– Dec 2017
A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients with "QuadrupleWild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab
Role: Principal Investigator
Funding: NATL SURG ADJUV BREAST & BOWEL
Feb 2012
– Jun 2016
UF Medical Guild
Role: Principal Investigator
Funding: UF MEDICAL GUILD
Contact Details
Phones:
- Business:
- (352) 273-7766
Emails:
- Business:
- carmen.allegra@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610